HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2005.092494v1 92/4/291    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hazir, T. Articles by Abbasi, S. Search for Related Content PubMed PubMed Citation Articles by Hazir, T. Articles by Abbasi, S. Topic Collections Relevant Articles

Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2–59 months: a multi-centre, double blind, randomised controlled trial in Pakistan

¹ Children’s Hospital, Pakistan Institute of Medical Sciences, Islamabad, Pakistan
² Child and Adolescent Health and Development, WHO, Geneva, Switzerland
³ Children’s Hospital, Lahore, Pakistan
⁴ Rawalpindi General Hospital, Rawalpindi, Pakistan
⁵ Nishtar Hospital, Multan, Pakistan

Correspondence to:
Correspondence to:
Dr Tabish Hazir
ARI Research Cell, Children’s Hospital, Pakistan Institute of Medical Sciences, Islamabad, Pakistan; arichi99{at}ariresearch.edu.pk

Introduction: WHO pneumonia case management guidelines recommend oral amoxicillin as first line treatment for non-severe pneumonia. Increasing treatment failure rates have been reported over a period of time, which could possibly be due to increasing minimum inhibitory concentrations of Streptococcus pneumoniae and Haemophilus influenzae for amoxicillin. Microbiological data show that this resistance can be overcome by increasing amoxicillin dosage. Based on this data, we examined whether we can improve the clinical outcome in non-severe pneumonia by doubling the dose of amoxicillin.

Methods: A double blind randomised controlled trial was conducted in the outpatient departments of four large hospitals in Pakistan. Children aged 2–59 months with non-severe pneumonia were randomised to receive either standard (45 mg/kg/day) or double dose (90 mg/kg/day) oral amoxicillin for 3 days and then followed up for 14 days. Final outcome was treatment failure by day 5.

Results: From September 2003 to June 2004, 876 children completed the study. 437 were randomised to standard and 439 to double dose oral amoxicillin. 20 (4.5%) children in the standard and 25 (5.7%) in the double dose group had therapy failure by day 5. Including the relapses, by day 14 there were 26 (5.9%) cumulative therapy failures with standard and 35 (7.9%) with double dose amoxicillin. These differences were not statistically significant (p = 0.55 and p = 0.29, respectively).

Conclusion: Clinical outcome in children aged 2–59 months with non-severe pneumonia is the same with standard and double dose oral amoxicillin. Non-severe pneumonia can be treated effectively and safely with a 3 day course of a standard dose.

This article has been cited by other articles:

				S. Awasthi, G. Agarwal, J. V. Singh, S. K. Kabra, R. M. Pillai, S. Singhi, B. Nongkynrih, R. Dwivedi, V. B. More, M. Kulkarni, et al. Effectiveness of 3-Day Amoxycillin vs. 5-Day Co-trimoxazole in the Treatment of Non-severe Pneumonia in Children Aged 2-59 Months of Age: A Multi-centric Open Labeled Trial J Trop Pediatr, July 8, 2008; (2008) fmn050v1. [Abstract] [Full Text] [PDF]

				No need to double antibiotic dose in children with non-severe pneumonia BMJ, June 9, 2007; 334(7605): 1189 - 1189. [Full Text] [PDF]

				Z. A Bhutta Dealing with childhood pneumonia in developing countries: how can we make a difference? Arch. Dis. Child., April 1, 2007; 92(4): 286 - 288. [Full Text] [PDF]

eLetters: